‹ ›
MYP_095343
← PREVIOUS NEXT → BACK
Basic Information
Unnamed
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
38 amino acids
C195H310N56O61
Standard
Sequence
TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL
Physicochemical Analysis
4414.89 Da
4.64
-3.58
-3.79
-0.0943
-0.48
0.62
-0.10
44.70
98.16
0.0789
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1933.58
-15.48
68.0
58.0
149.0
312.0
5.0
40.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0100768 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098-T651 virus
0.044 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 64440 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0110795 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
Evidence URLhttps://patents.google.com/patent/US20100261876A1/en PatentUS 2010/0261876 A1
RECORD: Rec_0111888 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV
HIV-1 IIIB
0.10 μg/mL
IC50
PaperNovel Methods of Synthesis for Therapeutic Antiviral Peptides Evidence URLhttps://patents.google.com/patent/US20100261876A1/en PatentUS 20100261876 A1
RECORD: Rec_0148977 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV 098-T1249 | CEM4 cells
0.005663 μM
IC50
Mammalian: 7.2 h; Yeast: >20 h; E. coli: >10 h
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0176281 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098 virus
0.045 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 64440 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
FIRST PREV 1 2 3 4 5 NEXT LAST
Showing 5 records on this page · Page 2 of 5